Mylan To Buy Abbott Business Line In $5.3B Deal - Presented by: The Aol. On Network

The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Mylan says the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands and headquartered in Pittsburgh, which help reduce tax expenses. The business to be acquired encompasses generic and specialty drugs sold in Europe, Japan, Canada, Australia and New Zealand.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
F $ 14.699 0.41 ▼ 2.72%
EBAY $ 56.256 3.60 ▲ 6.83%
PBR $ 14.095 0.61 ▼ 4.12%
BAC $ 17.075 0.07 ▲ 0.38%
AAPL $ 101.24 1.13 ▲ 1.13%
GPRO $ 89.82 1.12 ▼ 1.23%
RAD $ 4.81 0.14 ▼ 2.83%
QQQ $ 98.80 0.15 ▲ 0.15%

As of 9/30/2014, 10:37 AM
More Most Active